NCT05510895View on ClinicalTrials.gov

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

January 31, 2025

Conditions
Colorectal CancerColon CancerBRAF V600EBRAF V600 MutationLocalized Cancer
Interventions
DRUG

Binimetinib

Triplet combination administered neoadjuvant and adjuvant, depending on TRG

Trial Locations (1)

20249

Hämatologisch-Onkologische Praxis Eppendorf, Hamburg

All Listed Sponsors
collaborator

Pierre Fabre Pharma GmbH

INDUSTRY

collaborator

Merck Serono GmbH, Germany

INDUSTRY

collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

lead

AIO-Studien-gGmbH

OTHER